ConductScience.org, home

Paper3910216

Carboplatin as a potentiator of radiation therapy.

Douple EB and 3 others. Cancer Treat Rev, 1985. Cited by 159 papers, by iCite.

Cite this record

ConductScience Library. Carboplatin as a potentiator of radiation therapy. Papers, record 3910216. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3910216

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Carboplatin as a potentiator of radiation therapy.
PubMed
Journal
Cancer Treat Rev
PubMed
Year
1985
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
159
iCite
Relative citation ratio, by iCite
5.96
iCite
Revised in PubMed
2019-10-22
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Douple EBE B
2Richmond RCR C
3O'Hara JAJ A
4Coughlin CTC T

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
NeoplasmsMajor topic
Organoplatinum CompoundsMajor topic
Radiation-Sensitizing AgentsMajor topic
Animals
Carboplatin
Combined Modality Therapy
Cricetinae
Cricetulus
Humans
Mice
Platinum

Source PubMed

Download CSV of topics

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 159 citations.

PMIDTitleJournalYearIn PapersSource
41059462Osteosarcoma of the appendicular skeleton in dogs: consensus and guidelines.Front Vet Sci2025https://conductscience.org/library/papers/41059462PubMed
40283954Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40283954PubMed
31196855Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.Clin Cancer Res2019https://conductscience.org/library/papers/31196855PubMed
30332335Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial.J Clin Oncol2018https://conductscience.org/library/papers/30332335PubMed
29761244Copper-tolfenamic acid: evaluation of stability and anti-cancer activity.Invest New Drugs2019https://conductscience.org/library/papers/29761244PubMed
29386671Metronomic administration of lomustine following palliative radiation therapy for appendicular osteosarcoma in dogs.Can Vet J2018https://conductscience.org/library/papers/29386671PubMed
27574453Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma.Onco Targets Ther2016https://conductscience.org/library/papers/27574453PubMed
26029027Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma.Radiol Oncol2015https://conductscience.org/library/papers/26029027PubMed
25755911Concomitant use of radiotherapy and two topoisomerase inhibitors to treat adult T-cell leukemia with a radiotherapy-resistant bulky disease: a case series.Am J Blood Res2014https://conductscience.org/library/papers/25755911PubMed
25493083The long-term outcomes of induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.Case Rep Oncol2014https://conductscience.org/library/papers/25493083PubMed
24772308Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer.Mol Clin Oncol2014https://conductscience.org/library/papers/24772308PubMed
24234333Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study.Tumour Biol2014https://conductscience.org/library/papers/24234333PubMed
23292146Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer.J Radiat Res2013https://conductscience.org/library/papers/23292146PubMed
20514254Clinical outcome in dogs with nasal tumors treated with intensity-modulated radiation therapy.Can Vet J2010https://conductscience.org/library/papers/20514254PubMed
20205484Pharmacotherapy options for locally advanced and advanced cervical cancer.Drugs2010https://conductscience.org/library/papers/20205484PubMed
19219603Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity.Cancer Chemother Pharmacol2009https://conductscience.org/library/papers/19219603PubMed
16722549Radiosensitizers in cervical cancer. Cisplatin and beyond.Radiat Oncol2006https://conductscience.org/library/papers/16722549PubMed
15299181Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study.Med Oncol2004https://conductscience.org/library/papers/15299181PubMed
12177791Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.Br J Cancer2002https://conductscience.org/library/papers/12177791PubMed
8519652Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.Br J Cancer1995https://conductscience.org/library/papers/8519652PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3910216

GET https://conductscience.org/api/papers/v1/3910216/cited_by?page=2